The FDA has paused releasing new publicly available complete response letters (CRLs), seeking to reduce litigation risk around disclosure of sensitive rejection details. The pause follows a citizen’s petition filed in April and comes as the agency works toward a more formal legal basis for future releases. For sponsors, the policy shift changes how quickly application-level feedback becomes visible to the market and may affect how investors and competitors interpret regulatory outcomes before re-submission. The FDA also indicated it is working on a policy framework for disclosure, suggesting a transition rather than a permanent removal of information.